BioSynchronicity – Diversity, Equity, Inclusion, and Accessibility (DEIA) Plan
“Injustice anywhere is a threat to justice everywhere.” – Dr. Martin Luther King, Jr.
BioSynchronicity Corporation is a relatively new and fast-growing female-owned USA-based company formed in June, 2020 with the vision of providing the world with affordable and reliable in vitro diagnostic testing technologies in the battle to fight the COVID-19 pandemic. BioSynchronicity is proud of its diversity, equity and inclusion, with a team which includes many races, cultures and ethnicities of the world. We are committed to incorporating Diversity, Equity, Inclusion and Accessibility (DEIA) in all that we do. We have a DEIA statement of commitment and guiding principles and have incorporated it into our standard operating procedures.
By giving opportunities and access to our tests to people and ethnicities located in economically disadvantaged regions of the world, we believe the BioSynchronicity C-Sync™ family of COVID-19 tests will make a significant difference in the lives of many people universally who currently may not have affordable and reliable in vitro diagnostic testing options. The BioSynchronicity Rochester, New York, office itself is located in a designated Opportunity Zone where we plan to launch and apply many of our DEIA initiatives as we grow.
The BioSynchronicity team will implement our plan to assure that economically disadvantaged, minority, veteran, disabled, indigenous, LGBTQ, or female owned businesses, organizations, and communities will benefit from our testing solutions. These businesses, organizations, and communities should have access to reliable rapid testing with quick reporting of results. Since minority and disadvantaged communities are known to suffer more serious health consequences from the effects of the pandemic, there should be an added benefit to health in those communities from our testing innovation that will help to create an environment that is safe and comfortable. All of our facilities and communication technologies will strictly adhere to ADA (Americans with Disabilities Act, 1990) accessibility standards.
At BioSynchronicity, we value the diversity of our staff and associates. We are committed to systematic change that promotes equity and inclusion for all staff and associates. We are committed to an ongoing practice of identifying and responding to the causes and impacts of inequitable norms, policies and procedures while working to create a culture that centers on care, equity, inclusion, and social justice.